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Abstract 
Background: This study aimed to investigate the initial dosage of methadone and factors affecting it in 
maintenance therapy. 
Methods: This cross-sectional, descriptive-analytic study was conducted on 157 individuals referring to 
a methadone maintenance therapy (MMT) clinic. The initial dosage of methadone was 20-45 mg 
which was adjusted during the treatment based on each patient's evaluation. Three groups were 
formed according to methadone dosage (less than 30 mg, between 30-50 mg, and more than 50 mg). 
Findings: Significant relations were observed between increased methadone dosage in the initial phase 
and marital status (P = 0.03), injection (P = 0.03), medical comorbidity (P = 0.009), and borderline 
personality disorder (P < 0.001). 
Conclusion: Further studies with larger sample size and including the history of previous 
detoxification, substance abuse, omission of self-recording, evaluation of women’s addiction and MMT 
program performance with counseling support should be performed. 
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Introduction  
Opioid dependency is a chronic and often 
recurrent disorder that causes several medical 
problems such as AIDS, hepatitis, and social 
problems. Due to its chronicity, longtime, or even 
sometimes lifelong, treatment with substitution of 
opioids, such as methadone, is necessary for 
decreasing physical and psychosocial problems. 
Considering how different psychosocial 
dimensions of problems associated with drug 
abuse affect the family of the addict, the huge 
number of Iranian people involved with 
addiction becomes obvious.1-6  
Due to its strategic situation in the Middle East 
and its young population, Iran is at a high risk of 
opium consumption.2,3 However; it differs from 
other countries in terms of type and style of 
opioid use. In addition, statistics show higher 
unsuccessful opioid withdrawal in the country. 
Although there are several kinds of treatment 
methods, most drug addicts do not achieve 
permanent abstinence and obtain a life-long habit 
of using opium.2,3 
Opioid addiction might be treated through 
detoxification or maintenance therapy. Several 
guidelines are suggested and followed for 
detoxification ranging from treatment of 
symptoms with sedative and hypnotic drugs in 
outpatient centers to ultra rapid detoxification. 
Outpatient detoxification has not been very 
successful since it highly depends on the active 
attendance of the patients in self–helping groups 
after the detoxification.2, 3 
Methadone maintenance treatment (MMT) is 
one of the treatments which not only prevents 
relapse, but also causes improvement in physical 
and psychosocial health of the patient. In addition 
to bringing stability into the patient’s life, MMT 
decreases the risk of transmission of infectious 
diseases such as HIV/AIDS, hepatitis C viral 
infection (HCV), hepatitis B viral infection (HBV), 
and tuberculosis, along with the risk of 
committing a crime, and illegal use of drugs.3,5,7-9  
Maintenance therapy is used with addicted 
subjects who have not been successful in opioid 
withdrawal. MMT is more successful than short 
time methadone therapy in prevention of 
relapse.9-11 However, a drawback of MMT is that 
the patients should at least be 18 and need to have 
been addicted for at least one year duration.9,10 
The dose of methadone is determined based 
on the kind and amount of the substance used, 
age, gender, psychosocial condition, and medical 
and psychiatric comorbidities. The comorbidity of 
substance related disorders is more in men than 
in women. In addition, not only depression is 
very prevalent among drug addicts, but also 
antisocial personality disorder is four times more 
common in them than in the general population. 
Based on Iran National Research Center for 
Addiction, MMT is started with an initial dose of 
20-30 mg methadone per day. During treatment, 
especially the first weeks, methadone dose is 
adjusted based on the patient's evaluation until he 
becomes stable.5,8 
In 1999, the U.S federal rules allowed not only 
the clinics but also the offices to perform MMT for 
drug addicts which enabled primary care 
practitioners to use methadone therapy in their 
private offices.  
Treatment aims to prevent withdrawal 
syndrome, i.e. it involves lowering craving to 
opioids and blocking euphoric and sedative 
effects of illegal use of opioid. 
In the first phase of methadone treatment, the 
patient will become ready for a steady state in 
which he usually takes a dose of 20 to 30 mg (with 
a maximum of 45 mg) of methadone. Methadone 
will be prescribed until the satisfactory dose is 
determined. Then, the patient would be examined 
for other chronic medical or psychiatric disorders. 
MMT is continued until the patient is proved to 
be ready for successful detoxification.9 
During the maintenance phase, a dose 80 to 
120 mg (or even higher) is required. In addition, 
longtime treatment is more effective than short 
time treatment in preventing relapse.4,5 
Based on the results of a recent review of notes 
of methadone clinics, urinanalysis of patients who 
had received methadone for at least 6 months 
revealed that 22% of them experienced illegal use 
of opioids. This report indicated that in 4 
methadone clinics in Philadelphia 23% of illegal 
use of opioids is more than 10 days during a 
month. Overall, one-year commitment to 
methadone programs with doses over 80 mg per 
day was more than programs employing lower 
doses. 
It’s impotent to increase the dose of 
methadone in MMT due to tolerance; otherwise 
the patients will be tempted to use illegal drugs.7,8  
Since, to our knowledge, no exact relation 
between initial dose of methadone and factors 
affecting this dose has been determined which in 
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most cases necessitates correction, we tried to 
recognize the factors affecting initial dose for 
having better conditions during the process of 
opioid withdrawal. 
 
Methods 
This analytic prospective study was conducted 
on 157 opiate dependents referred to an MMT 
clinic. Since the only source of information about 
drug abuse was the participants themselves, 
they were first asked about demographics, 
amount and type of drugs they used, duration of 
use, and simultaneous use of other medicines. 
Then, the obtained data was recorded in files. 
Patients were evaluated and visited by a 
psychiatrist as soon as starting this treatment. 
Methadone was started with a minimal dose of 
20 mg and maximum dose of 45 mg per day 
based on the type and amount of the drug used, 
as well as physical and psychiatric disorders. 
During the treatment, appropriate decisions 
were taken considering the evaluations each 
patient made. The dose of methadone was 
increased to a maximum of 125 mg during the 
first 2 weeks which was continued if necessary.  
The dose of methadone was determined 
based on the amount of opium used. Patients 
who used more than 4.5 g of opium or 1 g heroin 
were prescribed with 30 mg methadone. If the 
patient was addicted to heroin with injection, 
dose of methadone was raised by 50%. If the 
patient was taking opium vapor, methadone 
dose was decreased 5 to 10 mg. In case of opium 
smoking or opium residue usage, the dose of 
methadone was increased for 5-10 mg (based on 
the adsorbed morphine). 
Patients were divided into three groups 
based on methadone dose. The first group 
received less than 30 mg methadone, the second 
group 30 to 50 mg methadone, and the third 
group over 50 mg methadone. 
According to our data, the patients with 
comorbid physical and psychiatric disorders or 
those using drugs such as benzodiazepines were 
more likely to require higher doses of 
methadone. 
After describing the variables, first, the 
differences in a group were evaluated using t–
test and ANOVA. Then, the most exact logistic 
regression model determining the required dose 
of methadone was tried to be formed based on 
all the studied variables. The precision of the 
regression model was investigated using R-
adjusted. 
 
Results 
Totally, 157 patients participated in this study 
including 145 (92.4%) males and 12 (7.6%) 
females. In addition, 53.4% were married, 32.1% 
were single, and 14% were widowers or 
divorces. 
The majority of participants had a high 
school diploma or a higher degree (50%). 
However, some only finished junior high school 
(23.1%), were high school dropouts (18%), or 
elementary school graduates (8.9%). Among 
those who had a job, 33.1% worked full-time and 
16.6% part-time. In addition, 57.9% were self-
employed. It took 62.6% of them less than 30 
minutes to get to the treatment center. Moreover, 
while 49.7% lived with their own family, 42.7% 
were living with their parents. 
Opium, sap, and heroin were used by 51.6, 
40.1, and 37.6 percent of the caes, respectively. 
Subjects used different methods of using drugs 
including eating (55.4%), smoking (54.1%), 
injection (15.9%), and snuffing (5.1%) (Table 1). 
Opium was used mainly with cigarettes 
(90.7%), anticholinergics (38.9%), alcohol 21.1%), 
cannabis (18.5%), tramadol (15.3%), 
benzodiazepines (6.4%). Among all, 26.3% had 
an experience of injection and 21.3% had been in 
jail. While 7.6% of the subjects had more than 10 
sex partners, each of HIV, HCV, HBV infections 
were seen in 2.4% of the participants (Table 1). 
A psychiatrist interviewed the patients to 
investigate the probability of axis I/II psychiatric 
disorders (based on DSM–IV–TR), other physical 
diseases, as well as abuse of other drugs. A 
significant correlation was found between 
increased dose of methadone and having 
borderline personality disorder or physical 
illnesses (Table 2). 
According to our findings, there were not 
any significant relations between the required 
methadone dose in the first 10 days and sex, age, 
education, source of income, the distance 
between the living place and the clinic, and the 
living situation. 
There was a negative correlation between 
marital status and employment with the dose of 
methadone in the first 10 days of treatment, i.e. 
those who were married or had a full-time job 
needed lower doses of methadone. 
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Moreover, while heroin had a positive 
correlation with methadone dosage, opium 
abuse and methadone usage were not 
significantly related. In addition, the way of 
abuse did not have a significant relation with 
methadone dose. Although simultaneous use of 
the drug with alcohol, benzodiazepines, 
tramadol, anticholinergic, and cannabis, led to 
the need for higher doses of methadone, the only 
significant increase in required dose of 
methadone was observed in case of 
antiparkinsonian anticholinergics (Table 1). 
There was a significant correlation between 
experiences of risky behaviors, such as injection 
and being in prison, and the required dose of 
methadone. However, no significant relations 
could be found between the dose of methadone 
and having more than 10 sex partners and HIV, 
HCV, and HBV infections (Table 1). 
The ordinary multivariable logistic regression 
model of factors affecting the initial methadone 
dosage is seen in table 3. 
 
 
Table 1. The relation between the initial methadone dose and type of substance, additional drugs, and history of 
high risk behaviors 
 Numbers of methadone pills (5mg) 
during the first 10 days 
 
P-value  > 10  6-10 < 6  
f % f % f % f %  
 Substance 
0.008 98 62.4 23 46.0 61 67.8 14 82.4 No Heroin 
59 37.6 27 54.0 29 32.2 3 17.6 Yes 
 Other drugs 
0.0001 96 61.1 20 40.0 61 67.8 15 88.2 No Anticholinergics 
61 38.9 30 60.0 29 32.2 2 11.8 Yes 
 High risk behavior 
0.001 112 73.7 26 53.1 75 84.3 11 78.6 No Injection 
40 26.3 23 46.9 14 15.7 3 21.4 Yes 
0.001 112 78.7 29 58.7 80 88.9 13 86.7 No Jail experience 
 
 
Table 2. The relation between the initial methadone dosage and comorbid physical and psychiatric disorders 
 Numbers of methadone pills (5mg) 
during the first 10 days 
 
P-value Total > 10 6-10 < 6  
f % f % f % f %  
 Axis I 
0.24 12 7.6 2 4 8 80.9 2 11.8 None 
34 21.7 12 24 15 20 4 23.5 MDD 
(Major depressive disorder) 
7 4.5 5 10 1 1.1 1 5.9 Bipolar 
3 1.9 0 0.0 2 2.2 1 5.9 Anxiety 
101 64.3 31 62 61 67.8 9 52.9 Others 
 Axis II 
0.0001 12 7.6 1 2 8 8.9 3 17.6 None 
18 11.5 11 22 7 7.8 0 0.0 BPD (borderline personality disorder 
35 22.3 23 46 11 12.2 1 5.9 APD (antisocial personality disorder) 
92 58.6 15 30 64 71.1 13 76.5 Others 
 Physical diseases 
0.01 97 63.8 23 46.9 62 71.3 23 46.9 No  
55 36.2 26 53.1 25 28.7 26 53.1 Yes 
 Other drug abuse 
0.06 88 84.6 23 71.9 55 90.2 10 90.9 No 
16 15.4 9 28.1 6 9.8 1 9.1 Yes 
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Table 3. Ordinary multivariable logistic regression model of factors affecting the initial 
methadone dosage 
95% CI OR Variable 
 Marital status 
 - 1 Single 
0.05-0.69 0.19 Married 
0.04-1.37 0.23 Others 
0.43-1.17 0.71 Age groups (Linear effect) 
0.13-1.32 0.41 Heroin use 
1.14-30.5 5.9 Injection 
1.46-13.9 4.5 Comorbid physical illnesses 
3.2-58.6 13.7 Bipolar Disorder 
 
Discussion 
In this study, participants were divided into 3 
groups based on the initial dose of methadone. 
The first group (less than 30 mg) included 17 
subjects, while the second (between 30 to 50 mg) 
and thirds (more than 50 mg) groups included 90 
and 50 participants, respectively. In the first 
group, while opium and cigarette consumption 
were the most frequent, heroin and opium 
inhalation and eating, along with using alcohol, 
cannabis, tramadol, anticholinergic, and 
benzodiazepine were the least frequent. Among 
all groups, the second group had the highest 
percentile of opium use, and lowest percentage of 
injection, cigarette smoking, history of 
imprisonment, and infection to HIV, HCV or 
HBV. Although the third group had the highest 
frequency of using heroin, alcohol, cannabis, 
anticholinergics, benzodiazepine, and tramadol, 
the differences were only significant in case of 
heroin (P = 0.008) and anticholinergics  
(P = 0.0001). Members of the third group also had 
the highest rate of inhalation, consumption, 
injection, and imprisonment, and the lowest rate 
of smoking, opium use, and having more than 10 
sex partners. 
Like Behdani et al.,12 we found a significant 
difference between the proportion of men and 
women since women do not tend to attend clinics 
for treatment. However, an exact estimation of sex 
proportion was not available (this could be 
highlighted by further studies investigating this 
proportion in different clinics and various 
regions). It seems the required dose of methadone 
is more in men than in women.  
The percentile of subjects aging less than 31 
rose from the first to the 3rd group. Subjects aging 
36-54 had the highest percentage, and also the 
highest frequency in the 1st group in comparison 
to others. In a study in Mashhad,12 most subjects 
aged 18-30 which would be logical since the city is 
near Afghanistan. However, the fact that the age 
of addiction is dropping needs attention. While in 
Kermanshah most drug addicts aged 25-29, 
substance abuse was most common in adults 
aging 30-34 in Tehran and Mazandaran. Most 
married individuals needed the lowest doses of 
methadone in contrast with single subjects  
(P = 0.01).  
In addition, the participants living in areas less 
than 30 minutes from the clinic needed lower 
doses. Similar to a previous national study in 
Kermanshah, Mashhad, Isfahan, and other cities, 
we found that more than half of the subjects had a 
high school diploma or higher, while the lowest 
frequency was associated with primary school 
education. More than half of the participants were 
married and 60% were financially independent. 
As it was suggested by Behdani et al.12 and 
national researches,13 spouse and family support 
had a significant role in motivating the addicts for 
withdrawal. They also found that methadone 
treatment caused an improvement in daily 
activities which made the patient able to keep his 
independent financial source and full-time job.  
It took 63% of the participants less than 30 
minutes to get to the clinic. Moreover, 50% lived 
with their families. In Washington, Deck and 
Carlson believed that availability barriers including 
simultaneous abuse of several substances, referral 
from legal system, living in team houses, and not 
having a financial source or a shelter, had 
significant relations with MMT. On the other hand, 
factors enhancing the access to methadone use 
were pregnancy and self referral treatments. Based 
on their findings, those living far from methadone 
clinics were more interested in referral.14 
The experience of injection was more common 
Methadone Treatment in Iranian Opiate Addicts Eslami Shahrbabaki et al. 
58 Addict & Health, Winter & Spring 2011; Vol 3, No 1-2. 
in the 3rd group, and those patients needed higher 
doses of methadone. Gill et al. claimed that 
although there were not any significant relations 
between antisocial personality disorders, risky 
sexual behaviors, infection to HIV, infusion, and 
methadone treatment, patients with antisocial 
personality disorder were more likely to become 
interested in the use of shared injection 
equipments, infection to HIV, and appearance of 
antisocial behaviors after the treatment cycle.7  
In contrast to the opium users, the percentile 
of heroin users rose from the 1st to the 3rd group. 
This was different from what Banta-Green et al. 
had found. They conducted a retrospective study 
to compare methadone maintenance doses 
between 2 user groups (prescription-type opioid 
primary (PTOP) and heroin abusers). They also 
investigated the type of substance used during 
the 12 month MMT period. In addition, they 
surveyed opiate use in the last 30 days, and 
heroin or any other substance used for the first 
time without heroin. After homogenizing 
demographic information, use of other kinds of 
substances, type of general support, and 
considering medical, psychiatric, social, legal, and 
family factors, no significant relation was 
observed between the differences in maintenance 
phase of treatment and the type of substance.15 In 
this study, while eating or inhalation of the 
substance increased the initial dose of methadone, 
smoking the drug decreased it. Moreover, 
although using alcohol, cannabis, 
anticholinergics, benzodiazepine, and tramadol 
increased the initial dose of methadone, the only 
significant relation was seen in case of 
anticholinergics (P = 0.0001). Cigarette smoking 
was most common in the first group (In fact, all 
participants this group were cigarette smokers). 
Epstein and Preston performed a retrospective 
clinical trial and announced that the use of 
cannabis was not effective on methadone dosage 
in heroin abusers.16 
The number of participant with depression and 
bipolar disorder increased from the second group 
to the third and it caused an increase in the initial 
dose of methadone. On the contrary, the percentile 
of having anxiety disorder had an inverse relation 
with the initial dose of methadone. Having 
borderline and antisocial personality disorders and 
physical illnesses, during the period of substance 
abuse increased the initial dose of methadone. 
However, the significant relations were only 
observed between the increased initial dose of 
methadone and physical disorders (P = 0.01) and 
borderline personality disorder (P = 0.001). In 
contrast, Gill et al. could not find this significant 
relation in their study.7  
Ahmadi suggested that since general health 
practitioners were interested in substance abusers, 
they could focus on risky individual behaviors or 
social factors to lower the risks.6 In an 
investigation in Australia, Haig reported that 
substance abuse and injection decreased after 
MMT. He suggested that like social programs, 
methadone programs should be spread and used 
in prisons, too.17 
Totally, as was shown by Krambeer et al., 
MMT was effective in lowering the use of 
injection and shared syringes. In addition, while 
daily doses of more than 80 mg of methadone 
led to better outputs, doses less than 40 mg per 
day were not enough or effective.8 However, the 
period for which MMT remains effective is 
affected by the type of the program, methadone 
dose and duration of treatment, and the time 
allocated to supporting services in the 
withdrawal program. It seemed that bigger 
numbers of volunteers in  the withdrawal group, 
the longer duration of treatment, and available 
supporting and counseling services from the 
beginning of the programs or even after 
finishing the treatment all caused better 
outcomes and saved more money.5 It is proven 
that MMT in substance dependents decreased 
illegal substance abuse, risk of infection and 
transmission of HIV, tuberculosis, hepatitis, and 
crimes.5 Access to appropriate supporting 
treatments lowered the risky behaviors. For 
instance, Avants et al. showed that supportive 
services from harm reduction groups promoted 
patients' self-control against sexual behaviors 
and drug abuse and therefore, increased the 
effectiveness of methadone therapy. Although 
MMT with group therapy seems expensive, it is 
considered as a method of withdrawal since 
similar programs have been successful in 
changing views towards HIV.11  
Furthermore, gathering information and 
getting feedback from patients behaviors by 
program developers can reduce crime rates and 
increase social rapport in volunteer groups.18,19 
Finally, apart from aforementioned elements 
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in this study, MMT should be investigated in 
combination with non pharmacological 
interventions such as group therapy and 
supportive counseling. 
Conflict of Interest: The Authors have no 
conflict of interest. 
 
Acknowledgment 
At the end, we gratefully thank Neurological 
Research Center of Kerman University of 
Medical Sciences for their financial and spiritual 
supports, and also all the patients and colleagues 
who helped us in this study. 
 
 
References 
1. Asaadi SH. Two important problem in 21st 
century: population growth and drugs. Tehran: 
Sepehr publishing; 1997. p. 127-38. 
2. Ministry of health and medical education. 
Practical guide for treatment of substance abusers. 
Tehran: Ministry of health and medical education; 
2002. p. 19-37.  
3. Mostashari G. Preliminary guideline in methadone 
maintenance therapy. Tehran: Department of 
prevention and treatment addiction, Ministry of 
health and medical education; 2002. Available from 
URL: http://www.sapto.hbi.ir/PDF/mmprimp1.pdf 
4. Morral AR, Belding MA, Iguchi MY. Identifying 
methadone maintenance clients at risk for poor 
treatment response: pretreatment and early 
progress indicators. Drug Alcohol Depend 1999; 
55(1-2): 25-33. 
5. Senay EC. Opioids: Methadone Maintenance. In: 
Galanter M, Kleber HD, Editors. The American 
Psychiatric Press textbook of substance abuse 
treatment. 1st ed. Washington, DC: American 
Psychiatric Press; 1994. p. 202-9. 
6. Ahmadi J. Methadone versus buprenorphine 
maintenance for the treatment of heroin-
dependent outpatients. J Subst Abuse Treat 2003; 
24(3): 217-20. 
7. Gill K, Nolimal D, Crowley TJ. Antisocial 
personality disorder, HIV risk behavior, and 
retention in methadone maintenance therapy. 
Drug Alcohol Depend 1992; 30(3): 247-52. 
8. Krambeer LL, von MW, Jr., Gabrielli WF, Jr., 
Penick EC. Methadone therapy for opioid 
dependence. Am Fam Physician 2001; 63(12): 
2404-10. 
9. Heimer R, Bray S, Burris S, Khoshnood K, 
Blankenship KM. Structural interventions to 
improve opiate maintenance. International Journal 
of Drug Policy 2002; 13(2): 101-11. 
10. Sadock BJ, Kaplan HI, Sadock VA. Biological 
therapies, Opioid receptor agonists. In: Sadock BJ, 
Kaplan HI, Sadock VA, Editors. Kaplan & 
Sadock's synopsis of psychiatry: behavioral 
sciences/clinical psychiatry. 10th ed. Philadelphia: 
Lippincott Williams & Wilkins; 2007. p. 1072-5. 
11. Avants SK, Margolin A, Usubiaga MH, Doebrick 
C. Targeting HIV-related outcomes with 
intravenous drug users maintained on methadone: a 
randomized clinical trial of a harm reduction group 
therapy. J Subst Abuse Treat 2004; 26(2): 67-78. 
12. Behdani F, Hebrani P, Arshadi H. 
Epidemiological characteristics of patients in 
methadone maintenance treatment, admitted in 
Hejazi Hospital, Mashad (2005-2006). The 
Journal of Fundamental of Mental Health 2007; 
9(33-34): 53-9. 
13. Razzaghi EM, Rahimi Movaghar A, Hosseini M. 
Madani S. Rapid Situation Assessment of Drug 
Abuse in Iran. Tehran: Iranian Welfare 
Organization; 2003. 
14. Deck D, Carlson MJ. Access to publicly funded 
methadone maintenance treatment in two 
western states. J Behav Health Serv Res 2004; 
31(2): 164-77. 
15. Banta-Green CJ, Maynard C, Koepsell TD, Wells 
EA, Donovan DM. Retention in methadone 
maintenance drug treatment for prescription-type 
opioid primary users compared to heroin users. 
Addiction 2009; 104(5): 775-83. 
16. Epstein DH, Preston KL. Does cannabis use 
predict poor outcome for heroin-dependent 
patients on maintenance treatment? Past findings 
and more evidence against. Addiction 2003; 
98(3): 269-79. 
17. Haig T. Randomized controlled trial proves 
effectiveness of methadone maintenance treatment 
in prison. Can HIV AIDS Policy Law Rev 2003; 
8(3): 48. 
18. Hser YI, Joshi V, Maglione M, Chou CP, Anglin 
MD. Effects of program and patient characteristics 
on retention of drug treatment patients. Evaluation 
and Program Planning 2001; 24(4): 331-41. 
19. Bianchi E, Maremmani I, Meloni D, Tagliamonte 
A. Controlled use of heroin in patients on 
methadone maintenance treatment. J Subst Abuse 
Treat 1992; 9(4): 383-7. 
 ﻣﻘﺎﻟﻪ ﭘﮋوﻫﺸﻲ
   .ﭘﺰﺷﻜﻲ، داﻧﺸﻜﺪه ﭘﺰﺷﻜﻲ، داﻧﺸﮕﺎه ﻋﻠﻮم ﭘﺰﺷﻜﻲ ﻛﺮﻣﺎن، ﻛﺮﻣﺎن، اﻳﺮان ﮔﺮوه روانﻣﺮﻛﺰ ﺗﺤﻘﻴﻘﺎت ﻋﻠﻮم اﻋﺼﺎب،  ،اﺳﺘﺎدﻳﺎر -1
  .ﭘﺰﺷﻜﻲ، داﻧﺸﻜﺪه ﭘﺰﺷﻜﻲ، داﻧﺸﮕﺎه ﻋﻠﻮم ﭘﺰﺷﻜﻲ ﻛﺮﻣﺎن، ﻛﺮﻣﺎن، اﻳﺮان ﮔﺮوه روان ،اﻧﺸﻴﺎرد -2
  .ﺳﺎزي در ﺳﻼﻣﺖ، داﻧﺸﮕﺎه ﻋﻠﻮم ﭘﺰﺷﻜﻲ ﻛﺮﻣﺎن، ﻛﺮﻣﺎن، اﻳﺮان اﭘﻴﺪﻣﻴﻮﻟﻮژي، ﻣﺮﻛﺰ ﺗﺤﻘﻴﻘﺎت ﻣﺪل ، ﮔﺮوهداﻧﺸﻴﺎر -3
  .ﻛﺮﻣﺎن، اﻳﺮانﭘﺰﺷﻜﻲ، داﻧﺸﻜﺪه ﭘﺰﺷﻜﻲ، داﻧﺸﮕﺎه ﻋﻠﻮم ﭘﺰﺷﻜﻲ ﻛﺮﻣﺎن،  روان ، ﮔﺮوهدﺳﺘﻴﺎر -4
  .، ﺗﻬﺮان، اﻳﺮانﻛﺎرﺷﻨﺎس ﺗﻐﺬﻳﻪ، وزارت ﺑﻬﺪاﺷﺖ، درﻣﺎن و آﻣﻮزش ﭘﺰﺷﻜﻲ -5
  .ﺳﺎزي در ﺳﻼﻣﺖ، داﻧﺸﮕﺎه ﻋﻠﻮم ﭘﺰﺷﻜﻲ ﻛﺮﻣﺎن، ﻛﺮﻣﺎن، اﻳﺮان ﭘﮋوﻫﺸﮕﺮ، ﻣﺮﻛﺰ ﺗﺤﻘﻴﻘﺎت ﻣﺪل -6
  .، ﺗﻬﺮان، اﻳﺮانﻛﺎرﺷﻨﺎس ﺻﻨﺎﻳﻊ ﺷﻴﻤﻴﺎﻳﻲ، وزارت آﻣﻮزش و ﭘﺮورش -7
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  ﭼﻜﻴﺪه
  .ﺷﺪاﻳﻦ ﻣﻄﺎﻟﻌﻪ ﺑﺎ ﻫﺪف ﺗﻌﻴﻴﻦ دوز اوﻟﻴﻪ ﻣﺘﺎدون در درﻣﺎن ﻧﮕﻬﺪارﻧﺪه و ﺷﻨﺎﺳﺎﻳﻲ ﻋﻮاﻣﻞ ﻣﺆﺛﺮ ﺑﺮ اﻳﻦ دوز اﻧﺠﺎم  :ﻣﻘﺪﻣﻪ
   TMMﻣﺮاﺟﻌﻪ ﻛﻨﻨﺪه ﺑﻪ ﻛﻠﻴﻨﻴﻚ  751ﺗﺤﻠﻴﻠﻲ ﺑﺎ  - ﻣﻄﺎﻟﻌﻪ ﺑﻪ ﺻﻮرت ﻣﻘﻄﻌﻲ، از ﻧﻮع ﺗﻮﺻﻴﻔﻲ :ﻫﺎ روش
ﮔﺮم،  ﻣﻴﻠﻲ 54ﮔﺮم و ﺣﺪاﻛﺜﺮ  ﻣﻴﻠﻲ 02ﻣﺘﺎدون ﺑﺎ دوز ﺣﺪاﻗﻞ . اﻧﺠﺎم ﺷﺪ( ypareht ecnanetniam enodahteM)
ﺗﺎ  03، ﺑﻴﻦ03ﺳﻪ ﮔﺮوه ﺑﺎ دوزﻫﺎي ﻛﻤﺘﺮ از . ﺪﺷﺮوع و دوز ﻣﻮرد ﻧﻴﺎز ﻫﺮ ﻓﺮد در ﻃﻲ دوره درﻣﺎن ﺑﺎ ارزﻳﺎﺑﻲ ﺑﻴﻤﺎر ﺗﻨﻈﻴﻢ ﺷ
  .ﮔﺮدﻳﺪﮔﺮم ﺗﺸﻜﻴﻞ  ﻣﻴﻠﻲ 05و ﺑﻴﺶ از  05
و اﺧﺘﻼل ( P = 0/900)ﻫﺎي ﺟﺴﻤﻲ  ، وﺟﻮد ﺑﻴﻤﺎري(P = 0/30) ، ﻣﺼﺮف ﺗﺰرﻳﻘﻲ(P = 0/30) وﺿﻌﻴﺖ ﺗﺄﻫﻞ :ﻫﺎ ﻳﺎﻓﺘﻪ
  .داﺷﺘﻨﺪ يدار ﺑﺎ اﻓﺰاﻳﺶ دوز ﻣﺘﺎدون ﻣﺼﺮﻓﻲ در ﻓﺎز اوﻟﻴﻪ ارﺗﺒﺎط ﻣﻌﻨﻲ( P < 0/100)ﺷﺨﺼﻴﺖ ﻣﺮزي 
ﻫﺎي ﻗﺒﻠﻲ، ﻣﺼﺮف  ﺗﺮ، ﺳﺎﺑﻘﻪ ﺗﺮك ﻋﻼوه ﺑﺮ ﺟﺎﻣﻌﻪ آﻣﺎري ﺑﺰرگ ،ﻳﻴﺪ ﻧﺘﺎﻳﺞ اﻳﻦ ﻣﻄﺎﻟﻌﻪﺄﺷﻮد ﺟﻬﺖ ﺗ ﺗﻮﺻﻴﻪ ﻣﻲ :ﮔﻴﺮي ﻧﺘﻴﺠﻪ
اي ﻣﻮرد ﺑﺮرﺳﻲ ﻗﺮار  ﺑﺎ ﺣﻤﺎﻳﺖ ﻣﺸﺎوره TMMدﻫﻲ، ﺑﺮرﺳﻲ اﻋﺘﻴﺎد زﻧﺎن و اﻧﺠﺎم ﻃﺮح   ﮔﺰارش ﻏﻴﺮ ﻣﺠﺎز ﻣﻮاد، ﺣﺬف ﺧﻮد
  .ﮔﻴﺮﻧﺪ
  .ﺷﺨﺼﻴﺖ، اﻋﺘﻴﺎد، ﻣﺘﺎدوناﺧﺘﻼل  :واژﮔﺎن ﻛﻠﻴﺪي
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